BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31248879)

  • 1. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
    Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
    Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of outer retinal abnormalities in eyes with vitreomacular traction without macular hole in the OASIS trial.
    Thomas AS; Duchateau L; Kozma-Wiebe P; Jaffe G
    Br J Ophthalmol; 2023 Jul; 107(7):1012-1017. PubMed ID: 35288439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
    Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
    Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Portuguese Experience with Ocriplasmin in Clinical Practice.
    Figueira J; Martins D; Pessoa B; Ferreira N; Meireles A; Sampaio A; Carneiro Â; Vaz F; Nascimento J; Moreno N; Roque J; Domingues M; Flores R; Teixeira C; Conde E; Henriques F; Proença H; Pita Negrão J; Barbosa M; Silva R; Vaz-Pereira S; Pereira Neves P; Gomes N; Raimundo M;
    Ophthalmic Res; 2016; 56(4):186-192. PubMed ID: 27438077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
    Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
    Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
    Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
    Wertheimer C; Haritoglou C; Laubichler P; Wolf A; Kaessmann K; Schumann RG; Priglinger S; Mayer WJ
    Ophthalmologica; 2018; 239(1):11-18. PubMed ID: 28954271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Microstructural retinal changes after pharmacological vitreolysis with ocriplasmin-an SD-OCT supported analysis].
    Groselli S; Wehrmann K; Rüther K; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2020 Mar; 117(3):260-266. PubMed ID: 31346704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELLIPSOID ZONE MAPPING AND OUTER RETINAL CHARACTERIZATION AFTER INTRAVITREAL OCRIPLASMIN.
    Itoh Y; Ehlers JP
    Retina; 2016 Dec; 36(12):2290-2296. PubMed ID: 27341665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome.
    Pirani V; Pelliccioni P; Cesari C; Carrozzi G; Cavallero E; Mariotti C
    Jpn J Ophthalmol; 2019 May; 63(3):255-261. PubMed ID: 30805734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.